Calcium-channel blockers inhibit human low density lipoprotein oxidation by oxygen radicals

Cardiovascular Drugs and Therapy

Volumn 10, Issue 4, 1996, Pages 417-424

  Napoli, Claudio ^a   Chiariello, Massimo ^a   Palumbo, Giuseppe ^a   Ambrosio, Giuseppe ^a,b,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Atherosclerosis; Calcium channel blockers; Low density lipoprotein; Oxygen radicals; Peroxidation

Indexed keywords

ACRYLAMIDE; APOLIPOPROTEIN B100; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; NIFEDIPINE; OXYGEN RADICAL; VERAPAMIL;

AGAR GEL ELECTROPHORESIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; HUMAN CELL; LIPID PEROXIDATION; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ARTERIOSCLEROSIS; CALCIUM CHANNEL BLOCKERS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FREE RADICALS; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; OXYGEN;

EID: 0029860461     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00051106     Document Type: Article

References (46)

1. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-809.
2. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: Basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995;91:2488-2496.
3. Weinstein DB, Heider JG. Antiatherogenic properties of calcium antagonists. Am J Med 1989;86:121-124.
4. Paoletti R, Bernini F. A new generation of calcium antagonists and their role in atherosclerosis. Am J Cardiol 1990; 66:28H-36H.
5. Sugano M, Nakashima Y, Matsushima T. Suppression of atherosclerosis in cholesterol fed rabbits by diltiazem injection. Arteriosclerosis 1986;6:237-241.
6. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest 1981;68:1366-1372.
7. Sievers RE, Rashid T, Garret J, Blumlein S, Parmley WW. Verapamil and diet halt progression of atherosclerosis in cholesterol-fed rabbits. Cardiovase Drugs Ther 1987;1: 65-69.
8. Sugano M, Nakashima Y, Tasaki H, Takasugi M, Kuroiwa A, Koide O. Effects of diltiazem on suppression and regression of experimental atherosclerosis. Br J Exp Pathol 1988; 69:515-523.
9. Thiery J, Niedmann PD, Seidel D. The beneficial influence of nifedipine on the regression of the cholesterol-induced atherosclerosis in rabbits. Res Exp Med 1987;187:539-567.
10. Betz E. The effect of calcium antagonists on intimai cell proliferation in atherogenesis. Ann NY Acad Sci 1988;522-399-410.
11. Jackson CL, Bush RC, Bowyer DE. Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion size. Atherosclerosis 1988;69:115-122.
12. Pauletto P, Scannapieco G, Borrione AC, et al. A nifedipine-sensitive smooth muscle cell population is present in the atherosclerotic rabbit aorta. Arterioscler Thromb 1991; 11:928-939.
13. Loaldi A, Polese A, Montorsi P, et al. Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris. Am J Cardiol 1989;64:433-437.
14. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 1990; 335:1109-1112.
15. Mak IT, Weglicki RA. Comparative antioxidant activities of propranolol, nifedipine, verapamil and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res 1990; 66:1149-1152.
16. Koller PT, Bergmann SR. Reduction of lipid peroxidation in reperfused isolated rabbit hearts by diltiazem. Circ Res 1989;65:838-846.
17. Mak TI, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Circ Res 1992;70:1099-1103.
18. Aruoma OI, Smith C, Cecchini R, Evans PJ, Halliwell B. Free radical scavenging and inhibition of lipid peroxidation by β-blockers and by agents that interfere with calcium metabolism. Biochem Pharmacol 1991;42:735-743.
19. Engineer F, Sridhar R. Inhibition of rat heart and liver microsomal lipid peroxidation by nifedipine. Biochem Pharmacol 1989;38:1279-1285.
20. Janero DR, Burghardt B, Lopez R. Protection of cardiac membrane phospholipid against oxidative injury by calcium antagonists. Biochem Pharmacol 1988;37:4197-4203.
21. Lupo E, Locher R, Weisser B, Vetter W. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with α-tocopherol. Biochem Biophys Res Commun 1994;203:1803-1808.
22. Napoli C, Postiglione A, Triggiani M, et al. Oxidative structural modifications of low density lipoprotein in homozygous familial hypercholesterolemia. Atherosclerosis 1995;118: 263-275.
23. Lowry OH, Rosebrough HJ, Farr AL, Randall RJ. Protein measurement with the folin-phenol reagent. J Biol Chem 1951;193:265-275.
24. Jialal I, Vega GL, Grundy SM. Physiologic levels of ascorbate inhibit the oxidative modification of LDL. Atherosclerosis 1990;82:182-191.
25. Slater TF. Overview of methods used for detecting lipid peroxidation. Methods Enzymol 1984;105:283-293.
26. Ambrosio G, Oriente A, Napoli C, et al. Oxygen radicals inhibit human plasma acethylhydrolase, the enzyme that catabolizes platelet-activating factor. J Clin Invest 1994;93: 2408-2416.
27. Ambrosio G, Flaherty JT, Duilio C, et al. Oxygen radicals generated at reflow induce peroxidation of membrane lipids in reperfused hearts. J Clin Invest 1991;87:1008-1016.
28. Becker LC, Ambrosio G. Myocardial consequences of reperfusion. Prog Cardiovasc Dis 1987;30:23-41.
29. Ambrosio G, Zweier JL, Duilio C, et al. Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. J Biol Chem 1993;25:18532-18541.
30. Marshall PJ, Kulmacz RJ, Lands WEM. Constraints on prostaglandin biosynthesis in tissues. J Biol Chem 1985; 262:3510-3517.
31. Henderson WR, Kaliner M. Immunologic and non-immunologic generation of superoxide from mast cells and basophils. J Clin Invest 1978;61:187-196.
32. Cronstein BN, Kramer SB, Weinsmann G, Hirschhorn R. Adenosine: A physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 1983;158: 1160-1177.
33. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987;84:7725-7729.
34. Salmon S, Maziere C, Theron L, et al. Immunological detection of low density lipoproteins modified by malondihaldehyde in vitro or in vivo. Biochim Biophys Acta 1987;920: 215-220.
35. Avogaro P, Bon GB, Cazzolato G. Presence of modified low density lipoproteins in humans. Arteriosclerosis 1988;8: 79-87.
36. Boyd HC, Gown AM, Walfbauer G, Chait A. Direct evidence for a protein recognized by a monoclonal antibody agonist oxidatively modified LDL in atherosclerotic lesions from Watanabe heritable hyperlipidemic rabbits. Am J Pathol 1989;135:815-825.
37. 100. J Lipid Res 1987;28:1466-1477.
38. Weisberger KH, Innenarity TL, Mahley RW. Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J Biol Chem 1976;253:9053-9062.
39. Henry PD. Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem. Am J Cardiol 1980;46:1047-1058.
40. Hammar SR, Blouin RA, McAllister RG Jr. Clinical pharmacokinetics of verapamil. Clin Pharmacokinet 1984;9:26-41.
41. Herbette LG, Vant Erve YMH, Rhodes DG. Interaction of dihydropyridine calcium channel antagonist with biological membranes: Lipid bilayer partitioning could occur before drug binding to receptors. J Mol Cell Cardiol 1989;21: 187-193.
42. 2+ antagonists in brain plasma membranes. Biochem Pharmacol 1989;38:2121-2127.
43. Simic MG, Hunter E. Reaction mechanism of peroxy and C-centered radicals with sulfhydryls. Free Rad Biol Med 1986;2:227-230.
44. Mak TI, Kramer JH, Weglicki WB. Antioxidant properties of active and inactive isomers of nicardipine in cardiac membranes, endothelial cells, and perfused rat hearts. Cor Art Dis 1992;3:1095-1103.
45. Weglicki WB, Mak TI, Simic MG. Mechanisms of cardiovascular drugs as antioxidants. J Mol Cell Cardiol 1990;22: 1199-1208.
46. Napoli C, Ambrosio G, Palumbo G, Chiariello M. Atherogenic oxidative modification of human low density lipoproteins may involve peroxidative chain reactions following initial oxygen radical attack. J Mol Cell Cardiol 1991;23(Suppl V):115-128A.